Reference:
DiDomenico, C., Clerico, D. and Leahey, A. (2015) Lack of vincristine infiltrates in patients with retinoblastoma receiving chemotherapy by peripheral intravenous lines. Pediatric Blood & Cancer. April 30th. [epub ahead of print].
[ctt tweet=”Vincristine extravasation rates from peripheral IV access devices http://ctt.ec/0Um94+ @ivteam #ivteam” coverup=”0Um94″]
Abstract:
The delivery route of chemotherapy for intraocular retinoblastoma has become controversial. One objection to systemic delivery is the need for central venous access. We cross-referenced a hospital vascular access database with our tumor registry to determine the incidence of chemotherapy infiltrates. Sixty-five patients received 270 cycles of chemotherapy via peripheral intravenous access. Vincristine infiltration was 0% (95% confidence interval [CI] 0-0.16%) while that of non-vesicant chemotherapy was 0.7% (95%CI 0.1-2.6%). Giving chemotherapy via peripheral access to patients with retinoblastoma is safe. It can decrease therapy costs and prevent central line associated blood stream infections.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]